William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating

Harrow, Inc. (NASDAQ:HROW) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 10, William Blair analyst Lachlan Hanbury-Brown initiated coverage of Harrow, Inc. (NASDAQ:HROW) with an Outperform rating and a $63 fair value estimate.

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout”

A doctor wearing a surgical mask performing a routine eye treatment at a hospital.

The analyst told investors in a research note that Harrow, Inc. (NASDAQ:HROW) began operations as a compounding pharmacy business but has since acquired an expanded portfolio of branded therapies with an attractive margin profile and growth, resulting in its expansion into the branded pharmaceutical segment.

The firm contended that Harrow, Inc.’s (NASDAQ:HROW) recently launched access and  affordability program, Vevye Access for All, “is rapidly accelerating growth.” It believes that the company is still early in the product adoption, and a complementary growth driver for this segment could be the recent reintroduction of Triesence.

Harrow, Inc. (NASDAQ:HROW) develops, produces, and sells innovative medications. The company’s operations are divided into two segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment manages the operations of the ImprimisRx business.

While we acknowledge the potential of HROW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.